Solta Medical Stock Rating Upgraded by Zacks (SLTM)
Solta Medical (NASDAQ:SLTM) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued on Tuesday, Analyst Ratings Network reports. The firm currently has a $2.30 price objective on the stock. Zacks‘ target price suggests a potential upside of 4.07% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Ascendiant Capital Markets downgraded shares of Solta Medical from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, August 7th. Separately, analysts at Roth Capital downgraded shares of Solta Medical from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, August 7th. Finally, analysts at Canaccord Genuity downgraded shares of Solta Medical from a “buy” rating to a “hold” rating in a research note to investors on Wednesday, August 7th. They now have a $2.50 price target on the stock, down previously from $3.50. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $2.77.
Shares of Solta Medical (NASDAQ:SLTM) traded down 2.71% during mid-day trading on Tuesday, hitting $2.15. 216,271 shares of the company’s stock traded hands. Solta Medical has a one year low of $1.44 and a one year high of $3.08. The stock’s 50-day moving average is $2.15 and its 200-day moving average is $2.1. The company’s market cap is $171.5 million.
Solta Medical (NASDAQ:SLTM) last released its earnings data on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. The company had revenue of $43.20 million for the quarter, compared to the consensus estimate of $45.97 million. During the same quarter in the previous year, the company posted $0.04 earnings per share. The company’s revenue for the quarter was up 15.8% on a year-over-year basis.
Solta Medical, Inc designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.